Yarbrough Capital LLC Sells 2,322 Shares of Zoetis Inc. (NYSE:ZTS)

Yarbrough Capital LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 54.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,945 shares of the company’s stock after selling 2,322 shares during the period. Yarbrough Capital LLC’s holdings in Zoetis were worth $317,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ZTS. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at about $31,000. First Personal Financial Services purchased a new position in shares of Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new position in Zoetis during the third quarter valued at approximately $33,000. Dunhill Financial LLC boosted its holdings in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP grew its position in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $169.30 on Friday. The business has a 50-day moving average price of $171.25 and a 200-day moving average price of $180.07. The firm has a market cap of $76.38 billion, a price-to-earnings ratio of 31.82, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm posted $1.36 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a $0.50 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.18%. The ex-dividend date is Tuesday, January 21st. Zoetis’s payout ratio is currently 32.52%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ZTS shares. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, JPMorgan Chase & Co. upped their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.